COLLEGIUM PHARMACEUTICAL, INC 8-K

What Happened
Collegium Pharmaceutical, Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Shareholders held May 14, 2026 (record date March 31, 2026). Of 32,406,969 shares entitled to vote, 29,210,926 were present in person or by proxy. Shareholders elected eight directors (Rita Balice-Gordon; Garen Bohlin; Michael Donovan; John Freund, M.D.; Vikram Karnani; Nancy Lurker; Carlos Paya, M.D., Ph.D.; and Gino Santini), approved the advisory vote on named executive officer compensation, and ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Total shares entitled to vote: 32,406,969; shares present: 29,210,926.
• Director elections: all eight nominees were elected (example vote totals: Michael Donovan 27,383,194 for; Nancy Lurker 27,379,677 for; Rita Balice-Gordon 25,890,238 for). Broker non-votes on director matters: 1,790,765.
• Advisory “say-on-pay” vote: 26,313,792 for, 1,100,723 against, 5,646 abstentions (1,790,765 broker non-votes).
• Auditor ratification: Deloitte & Touche LLP ratified with 28,953,181 for, 252,815 against, 4,930 abstentions (no broker non-votes reported for this item).

Why It Matters
Board elections determine who will oversee strategy, governance and management decisions for the coming year; all eight nominees were approved by shareholders. The affirmative advisory vote on executive compensation signals shareholder support for the company’s pay practices (non-binding). Ratification of Deloitte as auditor confirms continuity of the company’s external financial review for fiscal 2026. Investors should note the size of broker non-votes, which reduced the number of shares voting on certain proposals.